How did ASX cannabis shares perform in FY22?

Here's a look at the sector's performance in the financial year just gone.

| More on:
A woman wearing a pink blouse and straw hat holds up a cannabis leaf with tall green cannabis plants in the background

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX cannabis shares were a mixed bunch in FY22 with several winners and losers 
  • The sector wasn't immune to broad market weakness and continued to soften throughout the back end of FY22
  • We've selected three shares to glance over to gauge performance for the last financial year

There were mixed fortunes for ASX cannabis shares in FY22. Among the bunch there were winners and losers, all while investors navigated broad-market volatility.

However, the sector wasn't immune to selling pressure. Like most pockets of the market, cannabis stocks, on the whole, finished down last financial year despite the industry's achievements.

Let's take a look at three selected shares from the bunch to see how they went in FY22.

Emyria Ltd (ASX: EMD)

Shares of Emyria finished FY22 around 5% higher.

The share raced to its 52-week high of 49.5 cents in November 2021, only to gyrate downwards for the remainder of the year.

Back in February, Eymyria announced it had broadened its MDMA analogue library. This was in collaboration with the University of Western Australia.

Then in May, it provided an update on this partnership, noting the pair had agreed to "substantially expand their collaboration" to develop novel MDMA-like medicines.

"To date, 85 compounds have been successfully screened with several compounds being prepared for preclinical testing to determine their therapeutic potential," Emyria said.

This year to date, the Emyria share price is down around 43%.

Incannex Healthcare Ltd (ASX: IHL)

At the other end of the spectrum is Incannex Healthcare, which lost 16% in FY22. The share rallied from lows of 24 cents in August 2021 and surged to highs of 70 cents by January.

From there, it was a series of peaks and troughs with the ASX cannabis share trading as low as 42 cents and as high as 73 cents and everywhere in between from January to April.

After a rollercoaster of volatility, investors finally unloaded their positions en masse in April and the trend continued until the financial year's end.

Around the time of its rapid decline, news the company executed a term sheet to acquire APIRx Pharmaceutical USA, LLC was received poorly by investors.

Alas, the downtrend has continued and Incannex hit its 52-week lows last week at 21 cents. It now trades at 24.5 cents apiece.

Cronos Australia Ltd (ASX: CAU)

Another ASX cannabis share worth mentioning is Cronos. Out of the three names mentioned here, it was the top performer, and managed to secure a 127% gain in FY22.

It has since slipped from those levels and trades at 20 cents apiece, having dipped 20% this week. Zooming out, however, the share has continued its upward trajectory over the past year or so.

Investors rewarded Cronos throughout the year after it provided a series of positive updates including a solid first half of FY22.

It realised cash flow from operations of $9 million for the half, after producing around $28 million in cash receipts for the six months.

Perhaps the larger news however was the merger with CDA Health Pty Ltd.

That was in December 2021 and made CDA the owner of Cronos. CDA is an importer, exporter and wholesaler of cannabis products in Australia. It's been around since 2017.

Investors must have seen the upside in the transaction, judging from the share's performance on the chart in FY22.

TradingView Chart

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »